Evaluation of a bivalent recombinant vaccine candidate targeting norovirus and rotavirus: Antibodies to rotavirus NSP4 exert antidiarrheal effects without virus neutralization. Issue 8 (6th May 2022)

• Record Type: Journal Article
• Authors: Cao, Han; Wu, Jinyuan; Luan, Ning; Wang, Yunfei; Lin, Kangyang; Liu, Cunbao
• Is Part Of: Journal of medical virology. Volume 94:Issue 8(2022)
• Page Start: 3847
• Page End: 3856
• Publication Date: 2022-05-06
• Subjects: adjuvant -- bivalent vaccine -- nonstructural protein 4 -- norovirus -- P particle -- PP‐VP8* -- protruding domain -- rotavirus; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.27809
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: We previously found that when tandemly expressed with SR69A ‐VP8*, nonstructural protein 4 (NSP4) of the rotavirus Wa strain exerts a minor effect on elevating the antibody responses targeting the rotavirus antigen VP8* of the 60‐valent nanoparticle SR69A ‐VP8* but could fully protect mice from diarrhea induced by the rotavirus strain Wa. In this study, we chose comparably less immunogenic norovirus 24‐valent P particles with homogenous (i.e., VP8* from rotavirus) and heterogeneous (i.e., protruding domain of norovirus) antigens and in more challenging rotavirus SA11 strain‐induced diarrhea mouse models to evaluate its main role in recombinant gastroenteritis virus‐specific vaccines. The results showed that although as an adjuvant NSP4 exerted limited effects on the elevation of norovirus‐specific or VP8*‐specific neutralizing antibody production, as an antigen it could confer potent protection, particularly when synergized with VP8*, in rotavirus SA11 strain‐induced diarrhea mouse models, possibly blocking the invasion of the intestinal wall by enterotoxin. NSP4 may be unnecessary for other recombinant vaccines as adjuvants, and its display mode should be evaluated specifically to avoid blocking coexpressed antigens in the norovirus P particles.